Home Science As China embraces AI, only 24% of US pharma execs bet on...
Science

As China embraces AI, only 24% of US pharma execs bet on it for drug-making

As China embraces AI, only 24% of US pharma execs bet on it for drug-making
Key Points

Pharmaceutical companies have embraced artificial intelligence in drug research almost universally, yet few company executives expect AI to actually make drugs succeed, according to a Citi survey released on Tuesday. “The biggest risk to the AI-powered drug discovery thesis is not that AI fails to accelerate discovery,” said John Yung, head of Asia healthcare research at the US investment bank. “The stronger risk is that acceleration does not translate into better drugs or higher probability...

Pharmaceutical companies have embraced artificial intelligence in drug research almost universally, yet few company executives expect AI to actually make drugs succeed, according to a Citi survey released on Tuesday. “The biggest risk to the AI-powered drug discovery thesis is not that AI fails to accelerate discovery,” said John Yung, head of Asia healthcare research at the US investment bank. “The stronger risk is that acceleration does not translate into better drugs or higher probability of...
China (LOCATION) AI (ORG) US (LOCATION) Citi (ORG) John Yung (PERSON) Asia (LOCATION)
Originally published by South China Morning Post Read original →